The usefulness of ambulatory blood pressure monitoring (ABPM) vs casual blood pressure measurement in the physicians practice (PM) for the routine management of patients with hypertension concerning total mortality and morbidity has been compared in a prospective, randomised, open multicentre study with a 5-year follow-up. The study was performed in general practitioners offices in Germany from 1991 to 1997. A total of 1298 patients with essential hypertension were included. Cardio-and cerebrovascular events, total mortality/morbidity and drug-saving effects in hypertensives treated according to two different methods of blood pressure measurement were the primary and secondary endpoints of the study. A total of 239 patients from group 1 (ABPM, n ‫؍‬ 651), and 208 from group 2 (PM, n ‫؍‬ 647) prematurely discontinued the study. The
Introduction
In recent years, ambulatory blood pressure (ABPM) has been increasingly used in hospitals and in the physician's office for diagnosis, clinical trials, and in particular for monitoring treatment of hypertension in selected patients. This method is considered to be a better predictor of cardiovascular risk in the individual patient. 1, 2 Moreover this procedure helps to better target patients who will benefit from antihypertensive drug treatment, and at the same time avoiding unnecessary antihypertensive treatment in patients with white coat hypertension. 3 ABPM also offers advantages for monitoring antihypertensive treatment. The possible superiority of ABPM in patients undergoing treatment is based on a large reason for discontinuation in 55 of these patients (20 from group 1 and 35 from group 2) was that they reached the main endpoint (total mortality/morbidity and cardio-and cerebrovascular events) of the study. The difference was statistically significant (P ‫؍‬ 0.037) in favour of group 1. Cardio-and cerebrovascular events also occurred in a lower number of patients (n ‫؍‬ 14) in group 1, as compared to group 2 (n ‫؍‬ 24). The difference however was not significant (P ‫؍‬ 0.097). A difference in a direct drug-saving effect could not be observed between the two groups but 22% of the initially screened patients were detected with the ABPM to have white coat hypertension and thus these patients did not receive antihypertensive treatment.
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number of blood pressure values measured during patients normal daily activity, which results in an improved evaluation of the patients blood pressure under stresses of everyday life. 4, 5 Furthermore the potency and duration of action of an antihypertensive agent can be recorded more effectively over the entire dosage interval. 6 Thereby, unnecessary intensified antihypertensive treatment can be avoided in patients who have higher casual in-office measured blood pressure than with ABPM. Alternatively, it offers the possibility to intensify antihypertensive therapy in those patients who have higher ABPM values as compared to blood pressure levels measured in the physicians practice.
To date little information exists in the literature concerning the prognostic benefits of ABPM. A number of studies have indicated that ABPM as compared to casual office blood pressure measurement shows a better correlation to hypertensive target organ damage and to cardiovascular events. [7] [8] [9] [10] [11] [12] [13] Nevertheless, there is a lack of prospective, longterm studies, which demonstrate the value of ABPM as compared to blood pressure measured occasionally in the physician's office. The important question, whether consistent use of ABPM will result in an improved prognosis of hypertensives and to a reduction in the use of antihypertensive medication as compared to in-office casual blood pressure measurement, still remains unanswered.
Therefore the following prospective, randomised, multicentre study was performed to answer the question, whether hypertensives managed on the basis of ABPM have a better prognosis and require a lesser number of antihypertensive drugs than those treated according to casual office blood pressure measurement.
Materials and methods
This prospective, open, randomised, multicentre study was approved by the Ethics Committee of the University of Göttingen, Germany. The study was conducted according to the Declaration of Helsinki.
14 There were 50 general practitioners who participated in this trial, and an independent Clinical Event Committee was used for evaluation of events. A total of 1500 patients were planned to be included in the study. According to the definition of the Deutsche Hochdruckliga (German High Blood Pressure League) the patient must present hypertension requiring treatment (after 5 min sitting), clinic blood pressure (RivaRocci method) Ͼ140 and/or Ͼ90 mm Hg in three measurements on two different days. Patients had to be between 35 and 65 years old.
Exclusion criteria were contraindication for ramipril treatment, manifest cardiac insufficiency (NYHY III-IV), higher-grade aortic or mitral stenosis, pregnant or lactating women, women of childbearing potential, patients with a progressive, potentially fatal disease (life expectancy Ͻ1 year), patients with alcohol or drug abuse, known hypersensitivity against angiotensin-converting enzyme (ACE)-inhibitor, history of Quincke's oedema, patients who received other investigational substances within 30 days or five half-lives of this drug (the longer will apply) before entry to this protocol, patients who have been included in a previous ongoing study, legally incapable patients or patients unable to give consent.
Patients receiving antihypertensive medication had a washout period of 4 weeks (when blood pressure increased to Ͼ165/95 mm Hg patients could be randomised before the end of these 4 weeks). The patients were then randomised into two groups: group 1 'ABPM' and group 2 casual office blood pressure measurement ('PM'). The patients belonging to group 2 were directly included into the study, and in the patients of group 1 an ABPM was performed in addition by using Space Labs equipment consisting of validated oscillometric 90207 monitors. 15 The ambulatory readings were programmed at 15-min intervals from 6 am to 10 pm and at 30-min intervals from 10 pm to 6 am according to the recommendations of the German Hypertension League. 16 If a hypertensive blood pressure profile was also documented during ABPM (average day blood pressure from 6 am to 10 pm) systolic Ͼ135 and/or diastolic Ͼ85 mm Hg or average 24 h blood pressure systolic Ͼ130 and/or diastolic Ͼ80 mm Hg, according to the guidelines of the German Hypertension League 16 these patients were included in group 1 of the study, and those with lower blood pressure values than mentioned above were defined as 'white coat hypertensives' and were not included.
Scheduled visits in both groups were after 2-4 weeks, 3, 6, 9, 12 months and 2, 3, 4, 5 years after inclusion. ABPM in group 1 was performed once a year or when change of treatment seemed to be necessary according to office blood pressure (Ͼ140 and/or Ͼ90 mm Hg) or clinical reasons. Office blood pressure was documented at each visit in both groups.
In group 1 office blood pressure was documented, but during the entire study period all required changes in antihypertensive medication were carried out on the basis of ABPM; ie, the antihypertensive treatment was to be intensified if the average day blood pressure exceeded 135 and/or 85 mm Hg, or the average 24-h blood pressure was above 130 and/or 80 mm Hg. In group 2, the decision to adjust the dosage of the antihypertensive medication was exclusively taken according to the blood pressure values measured in the physician's practice. The treatment was to be intensified if office blood pressure values were above 140 and/or 90 mm Hg (mean of three measurements). In patients of this group ABPM was not performed. The patients were included in this study from 1991 to 1993, and monitored for an average period of 4 -7 years (maximum 6 years, minimum 4 years). The study was terminated in July 1997.
To ensure a comparable antihypertensive treatment in both groups, the ACE inhibitor ramipril was used as baseline drug starting with 1.25 mg o.d. in both the groups. The dosage was titrated up to 5 mg o.d. if necessary for normalising blood pressure during the first 4 -6 weeks. In the event of undesirable reactions or the need for a combination treatment according to the guidelines of the German Hypertension League, a calcium antagonist (felodipine 5 mg o.d. or nifedipine ret 10 mg t.d.), or a diuretic (hydrochlorothiazide 12.5 mg o.d.), or a beta-blocker (metoprolol 100 mg o.d.) could be administered alternatively or added to ramipril on physicians preference.
Definition of events
Cardiovascular events were defined as all (fatal and non-fatal) myocardial infarctions, all (fatal and nonfatal) strokes, and all other cardiovascular deaths. The diagnosis of these events required electrocardiograms or hospital records or necropsy reports.
Drug score
For comparison of antihypertensive therapy all medication was estimated by a drug-score which was based on the daily recommended dosage of each drug (ϭ 1 pt, half of recommended dosage ϭ 0.5 pts, double-dosage ϭ 2 pts). 
Statistical methods
Statistical analysis was completed on an intentionto-treat basis for all treated patients (with exception of patients with white coat hypertension). For evaluation of the demographic data with respect to the homogeneity of the two groups, the Student's t-test was used for age, body mass index, and baseline blood pressure, and a chi-squared test for sex. The size of the study population, the concomitant diseases, and reasons for premature study discontinuation were evaluated on the basis of frequency comparisons (chi-squared test, or if numbers of cases were small, with Fischer's exact test).
A correction of multiple t-tests was used for the comparison of average blood pressure values at individual measured time points. The Student's t-test was used for comparing the mean values of biochemical variables between the groups. The Wilcoxon-Mann-Whitney test was used for testing for differences in the dosage of the baseline drug ramipril between the two groups at the conclusion of the study.
Results

Patient population
A total of 1506 patients were screened for the study. Of these 1298 were finally enrolled to the two groups. Group 1, ABPM (n ϭ 651); group 2, casual practice blood pressure measurement (PM) (n ϭ 647). For inclusion of 651 patients in group 1, ABPM was performed in 859 patients. In 189 (22%) of these patients, white coat hypertension was detected, with increased casual blood pressure values (Ͼ140/90 mm Hg) measured in the physician's practice, but normotensive 24-h blood pressure values (Ͻ130/80 mm Hg) with ABPM.
These 189 patients were not enrolled to the longterm-study. In 19 patients ABPM was either not carried out correctly or the patients refused to repeat ABPM, and therefore were not enrolled to the study.
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Of the total 1298 patients included and treated in the study, 705 were female, and 593 male, the average age was 54.3 ± 9.4 years. Groups 1 and 2 were comparable, and no differences in age, sex, body mass index, nicotine and alcohol consumption, concomitant use of statins or aspirin, family history of cardiovascular diseases, concomitant diseases including previous cardiovascular events, average casual office blood pressure values and biochemical variables could be observed. The patients were followed up for an average of 4.7 years. Concomitant diseases which prevailed in the two groups are summarised in Table 1 .
Patients discontinuing the study
From the total of 1298 patients who entered the study, 851 patients completed the study according to the protocol. The number of patients discontinuing the study in each group over the 5 years of follow-up is shown in Figure 1 .
Although a higher number of patients in group 1, Figure 1 Number of patients continuing the study in the two groups over the 5 years of follow-up period.
as compared to group 2, discontinued the study the difference was however not significant. Of the total 447 patients prematurely dropping out of the study, 239 were in group 1 and 208 in group 2. A total of 308 patients out of the 447 discontinued the study due to protocol violation. There were 174 patients from group 1 and 134 from group 2. The difference between the groups was significant (P ϭ 0.0108). The reasons for discontinuation were protocol infringements, non-compliance of the patient to antihypertensive medication, patient shifting residence (n ϭ 62), centres discontinuing their participation in the study (five centres ended their co-operation for personal reasons (two practitioners died (n ϭ 52 patients), three collegues retired (n ϭ 81 patients)). By telephone contact it was possible to get the main information of 113 patients. They were still alive at least to the end of the study period and none of them suffered from a major cardiovascular event. The reason for the higher number of dropouts in group 1 was because of repeat ABPM, which was not tolerated by some patients. The number of lost for follow-up patients with no further information is 195 (15%).
Forty-five patients in group 1 and 39 in group 2 discontinued antihypertensive treatment due to drug-related adverse effects, these being mainly cough and allergic reactions. A significant difference between the groups could not be observed.
Reaching the combined study endpoint (total mortality/morbidity and cardiovascular events) was the reason for 55 patients (20 in group 1 vs 35 in group 2) to discontinue the study. This difference was significant (P ϭ 0.0366) in favour of group 1.
Also a lower number of cardio-and cerebrovascular events were observed in group 1 in comparison to group 2 (14 vs 24 events). Due to the small number of these events in total, the difference was significant on 10% level only.
The cardio-and cerebravascular mortality was comparable with six cases each in the two groups. Non-vascular endpoints did not differ significantly in the two groups, nor did total mortality (11 vs 14) .
Blood pressure and heart rate
The changes in mean values of systolic and diastolic blood pressure measured in the physician's office during the course of the treatment period in the group 1 (ABPM) and group 2 (PM) are depicted in Figure 2 . Although the baseline systolic blood pressure levels at the start of the study (group 1: 165.9 ± 17.3/100 ± 10.1 mm Hg, group 2: 167.6 ± 16.9/99.5 ± 10 mm Hg) were 1.7 mm Hg higher in group 2, the lowered blood pressure values achieved by active treatment during the entire study period are comparable in both the groups, and show no difference at any measured time-point over the average study period of 4.7 years. In group 2 59.7% of patients achieved target blood pressure. Heart rate was comparable as well (76.3 ± 9.8 vs 75.7 ± 10.9 per min) in both groups.
The mean systolic and diastolic blood pressure measured by ABPM in group 1 declined during the course of treatment from 143.7 ± 13.1/89.3 ± 9.2 No difference in the mean values of biochemical variables such as serum-cholesterol, serum-triglycerides and renal function could be detected between the two groups during the study period.
Consumption of antihypertensive drugs
A total of 68.7% of patients in group 1 and 68.3% of those in group 2 required ramipril as monotreatment. A combination of two antihypertensive agents was needed in 23.8% and 25.1% of the patients of group 1 and 2 respectively, and only 7.5% of the patients in group 1 and 6.6% in group 2 had to be treated with a combination of more than two antihypertensive drugs.
Also no significant difference could be observed in the number of ramipril dose-titration steps required in the two groups. Only in group 2 (PM) was there a slightly higher number of prescriptions of the 5 mg ramipril dosage, and in group 1 (ABPM), a slightly higher number of prescriptions for the lower dose of 1.25 mg ramipril. This indicates a trend to a lower ramipril dose requirement in group 1, as compared to group 2.
When the total antihypertensive drug prescriptions were evaluated with the help of a drug scoring system, no difference could be found in the number or dosage of drugs prescribed in the two groups. Therefore it could be concluded that there was no noticeable direct antihypertensive drug-saving effect in both of the groups. In order to determine the reason for the absence of differences in the drug-saving effect the values of blood pressure achieved using the in-office blood pressure measurement and ABPM were additionally evaluated.
Forty-eight percent of the total blood pressure values measured at any visit were found to be in the normal range according to each of the two measurement methods employed. Thus both these modalities were in good agreement in nearly half of the total blood pressure values measured in the study. In 21.1% of the blood pressure values measured, they were found to be elevated with both the methods (ABPM and in-office measurement) employed. A total of 17.7% of the blood pressure measurements performed in the office were elevated (Ͼ140/90 mm Hg), but in the normal range when measured by ABPM (Ͻ135/85 mm Hg). This was defined as 'white coat hypertension' and in these patients a drug-saving effect was possible. On the other hand 13.2% of blood pressure values measured in the physician's office were in the normal range (Ͻ140/90 mm Hg), but elevated (Ͼ135/85 mm Hg) when measured by ABPM. This was defined as 'reverse white coat hypertension', and in these patients intensified drug treatment was necessary, inspite of normotensive inoffice blood pressure values. The number of patients in whom antihypertensive drugs could be reduced was therefore slightly higher than the number of patients requiring intensified drug treatment. This probably explains why overall no drug-saving effect was achieved in this study. One can also conclude that on the basis of only in-office blood pressure measurement in group 1, 30.9% of the patients (17.7% 'white coat hypertension' and 13.2% 'reverse white coat hypertension') would have been classified differently.
Discussion
This prospective randomised study, is to our knowledge the first long-term trial investigating the benefit of consistent use of ABPM as compared to casual blood pressure measurement in the physician's office, during 5 years of antihypertensive treatment.
The results show, that in comparison to antihypertensive treatment based only on office blood pressure measurement, the consistent use of ABPM for monitoring treatment resulted in a significantly improved prognosis, with a reduction in cardiovascular morbidity and total mortality. This success observed in the group with consistent ABPM was accompanied, however, by a significantly higher number of patients rejecting this procedure due to inconvenience caused. A direct drug-saving effect could not be observed during long-term treatment based on ABPM.
The question that arises is whether the observed reduction in endpoints in group 1 can be explained by better and reliable blood pressure control. Taking into consideration the in-office blood pressure measurement which was performed in both groups, no difference in blood pressure behaviour whatsoever in the two groups could be detected. Differences in blood pressure control by means of in-office blood pressure measurement cannot therefore be the explanation for the observed difference in prognosis. However during evaluation of in-office blood pressure values in group 1, as compared to values obtained by ABPM, it was found that due to the limits of blood pressure values defined by the German Hypertension League, 30.9% of the patients in group 1 had their antihypertensive treatment changed on the basis of ABPM, which would not have occurred
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on the basis of in-office blood pressure measurement. All these patients have been classified differently, if only in-office blood pressure measurement would have been performed. The antihypertensive treatment in these patients was changed according to values measured by ABPM, this would also not have happened if only in-office blood pressure measurement had been done. Assuming that a similar percentage of patients also exists in group 2, the better blood pressure control could then be the reason for the prognostic difference observed in favour of group 1.
Moreover it should be noted that in group 1, 22% of screened patients identified as having white coat hypertension were not included in the study, while in group 2 probably a similar number of these patients with low risk 2, 17 were treated. It can be speculated that the observed differences in main endpoints would have been more pronounced, if patients with white coat hypertension in group 2 were also excluded from the study. Furthermore, various studies have shown that blood pressure measured by ABPM correlates better with the occurrence of hypertensive end-organ damage-in particular with left ventricular hypertrophy and microalbuminuria-than with casual blood pressure values measured in the physicians practice. 8, 11 The reason for the superiority of ABPM is probably due to the greater number of blood pressure readings taken under the actual situation of daily life, which represents a true blood pressure profile of the patient. ABPM allows a more accurate selection of patients for treatment and detects patients with white coat hypertension, in whom treatment is not necessary. 3 A further explanation for better prognosis observed in group 1 could be that due to consistent use of ABPM, the patient was closely attended to, and cared for more intensively by the patient's physician. As a result, patient compliance, detection of other risk factors, and treatment may have been improved. Although this could not be recorded by statistical analysis, this possibility however cannot be ruled out with certainty.
The observed reduction in morbidity and mortality in group 1 in this study is therefore probably due to a combination of a number of factors, such as improved selection of patients for treatment, more intensive care of the patients, resulting in a better and reliable control of patients blood pressure, and improved prognosis.
A drug-saving effect could not be observed in the two groups. A comparable number of patients in both the groups received monotherapy (ramipril) or a combination of two or three antihypertensive drugs. The quality of blood pressure control seems to have been better in the ABPM group, 30.9% of the patients in group 1, who were 'falsely' classified on the basis of in-office blood pressure measurement were 'correctly' reclassified and adequately treated.
In order to find possible reasons for the absence of drug-saving effect of treated patients in the study, the blood pressure values measured by ABPM and in the physicians office of group 1 were compared. According to in-office blood pressure measurement 17.7% of the patients would have received antihypertensive treatment, which was not necessary by using ABPM. On the other hand 13.2% of cases in group 1 had normotensive blood pressure values on the basis of in-office measurement, but elevated blood pressure values using ABPM, and therefore received more effective antihypertensive treatment. Since the difference between patients requiring increased antihypertensive drugs (13.2%) vs reduction of drugs (17.7%) is rather small, no significant drug-saving effect could be found using the two different methods of blood pressure measurement in group 1. However a trend to use lower dosages of ramipril could be observed in group 1 (ABPM) as compared to group 2 (PM).
An important aspect which should be taken into account when discussing the drug-saving effect is that antihypertensive treatment in patients with white coat hypertension could be avoided in 22% of the initially screened patients. This percentage is in accordance with dates from different studies. If this percentage would be included in the evaluation, a considerable drug-saving effect resulted. Such a drug-saving effect has been shown in a randomised control study by Staessen and co-workers. 4 On the other hand it is important to control patients with white coat hypertension carefully because many of them develop a manifest hypertension even within a short period. [18] [19] [20] In conclusion, this prospective, randomised study shows that consistent use of ABPM in hypertensives results in an improved patient prognosis compared to casual blood pressure measurement in the physician's office.
